▲ +37.91% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Fulgent Genetics in the last 3 months. The average price target is $55.80, with a high forecast of $100.00 and a low forecast of $20.00. The average price target represents a 37.91% upside from the last price of $40.46.
The current consensus among 5 investment analysts is to hold stock in Fulgent Genetics. This rating changed within the last month from a Buy consensus rating.
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.